Hashemzadeh Mohammad Sadegh, Esmaeili Gouvarchin Ghaleh Hadi, Mohammadi Mozafar, Yousefpoor Yaser, Rezaei Ehsan, Alishiri Gholamhossein
Nanobiotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Adv Pharm Bull. 2024 Jul;14(2):483-495. doi: 10.34172/apb.2024.037. Epub 2024 Mar 11.
Rheumatoid arthritis (RA) is a type of autoimmune disease that results in chronic inflammation of the joint synovial tissue, leading to joint damage and significant disability. Despite ongoing research, the exact cause of RA remains unclear, and current treatments have limitations. This study explores the potential of utilizing interleukin-1 receptor antagonist (IL-1RA) and anti-inflammatory macrophages polarized in the vicinity of the supernatant from allogeneic mesenchymal stem cells (MSCs) as a novel therapeutic approach for RA.
An expression cassette containing the gene was constructed and expressed in BL21. The resulting protein was purified and stabilized for use in in vivo experiments. Bone marrow MSCs were isolated and used to produce anti-inflammatory M2 macrophages from the isolated peripheral blood monocytes. The macrophages were then used to treat mice with RA induced by collagen type II.
The combination of IL-1RA and M2 macrophages improved clinical and histopathological symptoms of the disease, reduced levels of inflammatory factors, and modulated the immune system in the treated mouse groups. The results showed that this combinatory therapy had a synergistic effect for RA treatment.
The simultaneous use of IL-1RA and M2 cells could be a promising approach for the treatment of RA. This combinatory therapy has the potential to improve the disease and decrease the severity of inflammation in patients with RA.
类风湿性关节炎（RA）是一种自身免疫性疾病，可导致关节滑膜组织慢性炎症，进而引起关节损伤和严重残疾。尽管研究不断，但RA的确切病因仍不清楚，且目前的治疗方法存在局限性。本研究探索利用白细胞介素-1受体拮抗剂（IL-1RA）和在同种异体间充质干细胞（MSCs）上清液附近极化的抗炎巨噬细胞作为RA新型治疗方法的潜力。
构建含 基因的表达盒并在BL21中表达。将所得蛋白质纯化并稳定化以用于体内实验。分离骨髓间充质干细胞，并用于从分离的外周血单核细胞中产生抗炎M2巨噬细胞。然后用这些巨噬细胞治疗由II型胶原诱导的RA小鼠。
IL-1RA和M2巨噬细胞的联合使用改善了疾病的临床和组织病理学症状，降低了炎症因子水平，并调节了治疗小鼠组的免疫系统。结果表明，这种联合疗法对RA治疗具有协同作用。
同时使用IL-1RA和M2细胞可能是一种有前景的RA治疗方法。这种联合疗法有改善疾病并减轻RA患者炎症严重程度的潜力。
